JY
SRNE

Jeff Yass’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Jeff Yass’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-738,700
Closed -$657K – 14117
2022
Q4 		$657K Sell
738,700
-271,000
-27% -$359K ﹤0.01% 7167
2022
Q3 		$1.58M Sell
1,009,700
-260,900
-21% -$592K ﹤0.01% 5468
2022
Q2 		$2.55M Sell
1,270,600
-192,000
-13% -$332K ﹤0.01% 4386
2022
Q1 		$3.41M Sell
1,462,600
-349,400
-19% -$1.09M ﹤0.01% 4382
2021
Q4 		$8.43M Sell
1,812,000
-169,400
-9% -$1.05M ﹤0.01% 2960
2021
Q3 		$15.1M Sell
1,981,400
-144,600
-7% -$1.23M ﹤0.01% 2305
2021
Q2 		$20.6M Buy
2,126,000
+293,000
+16% +$2.33M ﹤0.01% 1987
2021
Q1 		$15.2M Buy
1,833,000
+127,000
+7% +$1.34M ﹤0.01% 2218
2020
Q4 		$11.6M Sell
1,706,000
-1,684,300
-50% -$13.5M ﹤0.01% 2322
2020
Q3 		$37.8M Buy
3,390,300
+2,298,100
+210% +$21M 0.01% 1027
2020
Q2 		$6.86M Buy
1,092,200
+860,600
+372% +$3.29M ﹤0.01% 2597
2020
Q1 		$426K Buy
231,600
+192,000
+485% +$553K ﹤0.01% 7266
2019
Q4 		$134K Sell
39,600
-55,700
-58% -$133K ﹤0.01% 9005
2019
Q3 		$204K Sell
95,300
-42,000
-31% -$97.9K ﹤0.01% 9059
2019
Q2 		$367K Buy
137,300
+18,200
+15% +$65.5K ﹤0.01% 7908
2019
Q1 		$566K Buy
119,100
+84,300
+242% +$221K ﹤0.01% 6033
2018
Q4 		$84K Buy
34,800
+16,300
+88% +$53.2K ﹤0.01% 8295
2018
Q3 		$81K Sell
18,500
-180,700
-91% -$1M ﹤0.01% 8680
2018
Q2 		$1.43M Buy
199,200
+180,800
+983% +$1.23M ﹤0.01% 4630
2018
Q1 		$95K Buy
+18,400
New +$131K ﹤0.01% 8724
2016
Q4 		– Sell
-46,400
Closed -$359K – 10344
2016
Q3 		$359K Buy
46,400
+36,100
+350% +$243K ﹤0.01% 6629
2016
Q2 		$58K Buy
+10,300
New +$65.8K ﹤0.01% 8209
2015
Q4 		– Sell
-129,400
Closed -$1.09M – 10145
2015
Q3 		$1.09M Buy
129,400
+71,500
+123% +$1.14M ﹤0.01% 5571
2015
Q2 		$1.02M Buy
57,900
+32,400
+127% +$416K ﹤0.01% 6177
2015
Q1 		$295K Buy
+25,500
New +$295K ﹤0.01% 8010

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Jeff Yass's SRNE Position: Q1 2023 in Review

Jeff Yass sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 1,689,671 shares — an estimated $1.5M sold.

Jeff Yass first reported a position in SRNE in Q4 2013 and held it in 29 quarters. The position peaked at $11.7M in Q2 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Jeff Yass reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Jeff Yass sold 1,689,671 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $1.5M.
  • Jeff Yass first reported a position in Sorrento Therapeutics, Inc. in Q4 2013 and held it in 29 quarters.
  • Jeff Yass's Sorrento Therapeutics, Inc. position peaked at $11.7M in Q2 2021.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Susquehanna International Group's 13F filing for Q1 2023, filed 16 May 2023.